Clinical value of upfront cranial radiotherapy in osimertinib-treated EGFR-mutant non-small-cell lung cancer with brain metastases

As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib has a powerful ability to penetrate the blood –brain barrier and a high potency for controlling brain metastases (BMs) from EGFR-mutant non-small cell lung cancer (NSCLC). The clinical value of cranial radiotherapy in osimertinib-treated NSCLC with BMs remains largely unknown.

Source: International Journal of Radiation Oncology * Biology * Physics - May 28, 2021 Category: Radiology Authors: Fan Yu, Jianjiao Ni, Wanqin Zeng, Yue Zhou, Tiantian Guo, Ya Zeng, Yang Zhao, Shuyan Li, Yida Li, Xi Yang, Liqing Zou, Shengping Wang, Quan Liu, Yuan Li, Li Chu, Xiao Chu, Luxi Ye, Wen Yu, Zhengfei Zhu Source Type: research